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dimensional model of the instrument with group type (exercise or control) as the 
criterion variable to assess model invariance. RESULTS: A total of 89 participants 
completed the trial of which 48 were in the exercise group. Evidence of variation in 
the factorial structure of the EPDS between groups was found suggesting the invari-
ance assumption may not be supported. CONCLUSIONS: The assumption that the 
outcome measure (EPDS) is invariant between groups within an RCT was not sup-
ported. Further investigation is required to evaluate the impact of outcome measure 
variance on treatment effects in clinical trials where self-report measure data is used 
as primary and/or secondary outcomes.
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OBJECTIVES: The prevalence of intrauterine device (IUD) use is low among women 
of reproductive age in the United States. The objective of this study was to examine 
the trend in IUD insertions and related medical expenditures between 2002 and 2007 
in a population of women covered by employer-sponsored health insurance (ESI). 
METHODS: We conducted a population-based study using the MarketScan Com-
mercial Claims and Encounter Enrolled Population database. We identiﬁed women, 
15–49 years old who ﬁled a claim for the insertion of an IUD or IUS (the Levonorg-
estrel-releasing IUD) between January 1, 2002 and December 31, 2007. We adopted 
the MarketScan national weights in order to generate nationally representative esti-
mates. RESULTS: The number of new IUD/IUS patients in the ESI-covered population 
doubled, from 70,851 (2/1,000 eligible women) in 2002 to 154,366 (8/1,000) in 2007. 
Meanwhile, the market share of the IUS increased from 35% to 80% of all IUD 
insertions. The mean copayment for IUD (IUS) devices decreased from $13.0 ($14.6) 
in 2002 to $3.5 ($3.6) in 2007 after adjusting for inﬂation (in 2007 dollars), and the 
percent of patients with zero copayment for the device and for the insertion procedure 
increased from 65% to more than 80% and form 58% to 73%, respectively. The 
average net reimbursement for the IUD increased 17.5% between 2002 and 2007, 
from $311.92 to $366.64, while that for the IUS increased 7.5%, from $405.36 to 
$435.49. CONCLUSIONS: The increase in medical expenditures associated with IUD/
IUS insertions from 2002 to 2007 was driven by the growth in IUS insertions. IUDs 
have lower contraceptive failure rates than other reversible contraceptive methods, 
and higher rates of IUD use should lead to fewer unwanted pregnancies. Additional 
research is needed to understand whether the recent growth in IUS insertions is related 
to changing provider attitudes and more favorable insurance coverage.
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OBJECTIVES: To document surgical treatment patterns of uterine ﬁbroid (UF) 
patients and total all-cause medical costs for UF patients in real-world practice settings 
using managed care claims data. METHODS: In this retrospective database study, 
women with a UF diagnosis between 15 and 51 years of age were selected between 
2000 and 2006. An index date was deﬁned as the date of ﬁrst observed UF diagnosis. 
All patients were required to have continuous plan enrollment 6 months pre- and 36 
months post-index date. Summary statistics for patient characteristics, probability of 
ﬁrst UF-related surgery, any repeat UF-related surgery, and total medical and phar-
macy costs (2007 US$) incurred 12 months post-index date were generated. RESULTS: 
A total of 109,595 patients met the study inclusion criteria. The mean age at UF 
diagnosis was 43 years and the mean Charlson score was 0.27. Patients with com-
mercial insurance accounted for 91% of the population, while 75% had an HMO 
or PPO plan. The probability of UF-related surgery was 30.2%, 35.0%, and 38.4% 
within the 12-month, 24-month, and 36-month follow-up periods, respectively. 
Among patients with a UF-related surgery during the 36 month follow-up period, 
79.6%, 7.3%, 3.3%, 13.0% had hysterectomy, myomectomy, UAE/UAO, and abla-
tion, respectively. Mean age at ﬁrst surgery (44 years) varied by surgery type with 
younger women more likely to undergo myomectomy. The rate of repeat surgery 
within one year of ﬁrst surgery ranged from 1.6% (hysterectomy) to 10.5% (ablation). 
The mean total cost for all UF patients was $9608, 12 months post-index date. 
CONCLUSIONS: A substantial proportion of patients undergo UF-related surgeries 
within one to three years of diagnosis, with hysterectomy being the most common 
surgery. UF-related surgeries present signiﬁcant clinical and economic implications 
that should be understood by private and public third party payers who bear the 
ﬁnancial burden of UF surgical care.
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OBJECTIVES: To assess length of stay (LOS) and costs attributable to ADHD among 
adolescents hospitalized with a primary diagnosis of ODD. METHODS: Patients 
12–17 years old with a primary diagnosis of ODD (ICD-9-CM code 313.81) were 
selected from the 2000 to 2006 Health care Cost and Utilization Project Nationwide 
Inpatient Sample (HCUP-NIS). Patients with a diagnosis of ADHD (ICD-9-CM codes 
314.00 and 314.01) comprised the study cohort and patients without an ADHD 
diagnosis comprised the control cohort. Study measures included demographics, hos-
pital characteristics, admission source, discharge disposition, LOS, and costs. General-
ized linear models accounting for the HCUP-NIS survey design were undertaken to 
adjust LOS and cost estimates. RESULTS: A total of 7,404 and 18,039 patients met 
the inclusion criteria for the study and control cohorts, respectively. Patients in the 
study cohort were 6.8 months younger than patients in the control cohort (13.8 versus 
14.4 years). A higher percentage of patients in the study cohort were male (71.3% 
versus 45.2%) or had Medicaid (57.1% versus 48.6%) compared to the control 
cohort. In both cohorts, the ER was the most common admission source, approxi-
mately 90% of patients had their discharge disposition recorded as routine, and most 
patients were treated in urban, teaching, or large bedsize hospitals. The study cohort 
had longer LOS and higher costs versus the control cohort (mean [SE] 9.48 [0.89] 
days and $8241 [$1356] versus 7.90 [0.59] days and $6466 [$709]). Regression 
analyses found the study cohort had signiﬁcantly longer LOS and higher costs versus 
the control cohort (by 2.5 days and $1338). CONCLUSIONS: Patients hospitalized 
with a primary diagnosis of ODD and a secondary diagnosis of ADHD had signiﬁ-
cantly longer LOS and higher costs compared to patients with ODD but without 
ADHD. Clinicians and health care decision-makers should be aware of the impact 
ADHD has on inpatient stays among patients with ODD.
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OBJECTIVES: This study employed a retrospective cohort design to examine patterns 
of duloxetine utilization and health care costs among elderly ﬁbromyalgia patients. 
METHODS: Pharmacy and medical claims were analyzed for ﬁbromyalgia patients 
aged 65+ with Medicare supplemental insurance who initiated duloxetine in 2006. 
The index date was deﬁned as the dispense date of the ﬁrst duloxetine prescription 
ﬁlled, with no duloxetine coverage in the prior 90 days. Patients were required to have 
at least 30 supply days of duloxetine in the 12 months post-index period. Individuals 
with any diagnosis of diabetic peripheral neuropathic pain or depression during the 
12 months pre-index period were excluded. Five study cohorts were constructed based 
on the index dosage: <30 mg, 30 mg, 31–59 mg, 60 mg, and >60 mg. Patterns of dulox-
etine use including changes in dosage, average daily dose (ADD), adherence to dulox-
etine (medication possession ratio≥0.8 as high adherence) were examined across study 
cohorts. Regression models were performed to estimate the differences in health care 
costs. RESULTS: A total of 566 ﬁbromyalgia patients were included, with 41, 163, 
47, 294 and 21 in the <30 mg, 30 mg, 31–59 mg, 60 mg, and >60 mg cohorts, respec-
tively. A total of 31.4% of patients experienced any dosage changes (increased dosage: 
25.8%; decreased dosage: 15.7%). Among those who changed dosage, patients in the 
31–59 mg cohort had the shortest time to change (81 days), and patients in the <30 mg 
cohort had the longest (149 days) time. ADD trended upward as index dose increased. 
Compared with patients in the 60 mg cohort, those in the <30 mg and >60 mg cohorts 
were less likely to be adherent (odds ratios 0.40 and 0.30, respectively, both p < 0.05). 
Post-index total health care costs were similar across cohorts. CONCLUSIONS: 
Dosage changes occurred most quickly in ﬁbromyalgia patients with an index dose of 
31–59 mg of duloxetine. Duloxetine ADD and adherence differ by index dosage, while 
health care costs remain similar.
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OBJECTIVES: Hypoactive sexual desire disorder (HSDD) is characterized by persis-
tent/ recurring deﬁciency of sexual fantasies or thoughts, and/or the absence of desire 
for sexual activity. Despite the potentially high prevalence of the condition, few studies 
have evaluated the cost of treating women with HSDD. The current study describes 
health care utilization and costs among women suffering from HSDD relative to 
women without evidence of female sexual dysfunction (FSD). METHODS: Women 
aged 18–64 with a diagnosis of HSDD (ICD-9-CM: 302.71) were identiﬁed using the 
Marketscan® Commercial Claims and Encounters Databases from Thomson Reuters. 
Women were identiﬁed between January 1, 1998-December 31, 2007 and were 
matched 1:3 to women without FSD (ICD-9-CM: 302.7x; 306.51) based on age, 
health plan type and months with medical/pharmacy beneﬁts. Utilization and costs 
were evaluated during the 12, 24 and 36- month periods following HSDD diagnosis. 
